Verona Pharma plc Sponsored ADR Forecast, price target & analysts
Verona Pharma plc Sponsored ADR Target price 2025 - Analyst rating & recommendation
Verona Pharma plc Sponsored ADR Classifications & Recommendation:
Verona Pharma plc Sponsored ADR Price Target
| Target Price | $80.30 |
| Price | $68.83 |
| Potential |
16.66%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Verona Pharma plc Sponsored ADR 2026 .
The average Verona Pharma plc Sponsored ADR target price is $80.30.
This is
16.66%
register free of charge
$93.00
35.12%
register free of charge
$72.00
4.61%
register free of charge
|
|
| A rating was issued by 10 analysts: 10 Analysts recommend Verona Pharma plc Sponsored ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Verona Pharma plc Sponsored ADR stock has an average upside potential 2026 of
16.66%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 42.30 | 315.87 |
| 646.73% | ||
| EBITDA Margin | -363.19% | 33.29% |
| 109.17% | ||
| Net Margin | -426.15% | 2.94% |
| 100.69% |
10 Analysts have issued a sales forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Verona Pharma plc Sponsored ADR Analysts have issued a net profit forecast 2025. The average Verona Pharma plc Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.13 | 0.11 |
| 208.70% | 105.16% | |
| P/E | 596.90 | |
| EV/Sales | 16.66 |
3 Analysts have issued a Verona Pharma plc Sponsored ADR forecast for earnings per share. The average Verona Pharma plc Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Verona Pharma plc Sponsored ADR...
Current Verona Pharma plc Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 21 2025 |
| Roth MKM |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 21 2025 |
|
Locked
Roth MKM:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 08 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jan 08 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
